title: PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab' antibody fragment after pulmonary delivery in three different species.
abstract: The PEGylation of antibody fragments has been shown to greatly prolong their residence time in the lungs in mice. The purpose of this research was to confirm the effect of PEGylation in higher animal species, that is, the rat and the rabbit. An anti-IL-17A Fab' antibody fragment was conjugated to a two-armed 40kDa polyethylene glycol (PEG) via site-selective thiol PEGylation. PEGylation did not significantly alter the binding activity of the Fab' fragment but it largely enhanced its inhibitory potency. PEGylation increased the residence time of the Fab' in the lungs of mice, rats and rabbits. Following intratracheal administration, the unconjugated Fab' was cleared from the lungs within 24h while large quantities of the PEGylated Fab' remained present up to 48h. No significant differences in clearance were noted between the three animal species although there was a tendency of longer residence time in higher species. PEGylation represents a promising approach to sustain the presence of antibody fragments in the lungs and to enhance their therapeutic efficacy in respiratory diseases.
authors.affiliation: Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery & Biomaterials, Brussels, Belgium.
authors.forename: Danielle
authors.initials: D
authors.lastname: Freches
authors.affiliation: Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery & Biomaterials, Brussels, Belgium.
authors.forename: Harshad P
authors.initials: HP
authors.lastname: Patil
authors.affiliation: Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery & Biomaterials, Brussels, Belgium.
authors.forename: Maria
authors.initials: M
authors.lastname: Machado Franco
authors.affiliation: Ludwig Institute for Cancer Research, Brussels, Belgium.
authors.forename: Catherine
authors.initials: C
authors.lastname: Uyttenhove
authors.affiliation: UCB Pharma, Slough, UK.
authors.forename: Sam
authors.initials: S
authors.lastname: Heywood
authors.affiliation: Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery & Biomaterials, Brussels, Belgium. Electronic address: rita.vanbever@uclouvain.be.
authors.forename: Rita
authors.initials: R
authors.lastname: Vanbever
mesh_terms: D000818:Animals; D001323:Autoantibodies / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000378:metabolism*; D020381:Interleukin-17 / Q000378:metabolism*; D008168:Lung / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051379:Mice; D041681:NIH 3T3 Cells; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000378:metabolism*; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D013045:Species Specificity
chemical_list: D001323:Autoantibodies; C508717:IL17A protein, human; D007140:Immunoglobulin Fab Fragments; D020381:Interleukin-17; D011092:Polyethylene Glycols
keywords: Monoclonal antibodies; PEGylation; Polyethylene glycol (PubChem CID: 174); Pulmonary drug delivery; Residence time; Rodents